Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion by Nio, Y et al.
Malignant effusion appears in the terminal stage of cancers,
especially in digestive organ cancer, lung cancer and breast cancer.
Despite the recent progress in multidisciplinary treatment
employing chemotherapy, radiotherapy, immunotherapy, hyper-
thermia and other therapies, the most effective therapy for
malignant effusion has not been established and the prognosis of
patients with malignant effusion is very poor.
The intracavitary (i.c.) administration of anticancer agents
(ACAs) has been applied for the treatment of malignant effusion;
however, most patients usually die within 3 months after initiation
of the therapy. In general, i.c. chemotherapy with bleomycin
(BLM) or cisplatin (CDDP), has been applied. Paladine et al
reported that i.c. BLM for malignant pleural effusion from lung
cancer resulted in a 63% response with a mean survival period of
41 days for responders; however, they indicated that various
malignancies showed different responses, and effusion from breast
and ovarian cancers responded well to i.c. chemotherapy (Paladine
et al, 1976). Osterowski (1986) reported that intrapleural (i.pl.)
BLM resulted in an 80.5% response for malignant pleural effusion
with a 1-year disease-free rate of 19%. He also reported that breast
carcinoma responded well to i.pl. BLM: for malignant ascites,
intraperitoneal (i.p.) BLM resulted in a 62.5% response with a
1-year survival rate of 6.25%. Rusch et al (1991) reported that
i.pl. CDDP and cytosine arabinoside (AraC) for patients with
malignant pleural effusion from various malignancies resulted in
39% response, and a median survival of 5.7 months. These reports
suggest that: (1) the response of effusions differs among the
primary diseases and effusion from breast carcinoma seems to
respond better than those from other malignancies; and (2)
peritoneal effusion is more resistant to i.c. chemotherapy than
pleural effusion. However, with respect to the effects of i.c.
chemotherapy on effusions from digestive organ cancers, there are
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Summary The current prospective randomized study was designed to compare the effects of intracavitary (i.c.) chemotherapy vs
immunotherapy vs immunochemotherapy for malignant effusion. Between 1992 and 1995, a total of 42 patients with malignant effusion were
registered, and 41 patients were eligible for statistical analysis. The primary diseases of the eligible patients included 27 gastric, four
colorectal, four pancreatic, three lung, two liver and one oesophageal cancers. The patients with malignant effusion were randomly assigned
into one of three i.c. therapeutic regimens: chemotherapy alone with weekly injection of anticancer agents (ACAs: cisplatin, mitomycin-C,
adriamycin, etc.) (Group A, n = 13); immunotherapy alone with weekly injection of streptococcal preparation OK-432 (Group B, n = 14); or
immunochemotherapy with ACAs and OK-432 (Group C, n = 14). The response of the effusion, patient survival and the kinetics of cytokines
in the effusion were compared. There were no differences in the patients’ backgrounds. The side-effects of the regimens included pain,
anorexia, fever, leucopenia and anaemia and there were no differences in their incidence among the three groups. One patient died after
cisplatin (CDDP) administration in Group A. Cytologic examination revealed that tumour cells in the effusion disappeared in 23% of Group A
cases, 36% of Group B cases and 36% of Group C cases. The malignant effusion did not disappear in any of the Group A cases; however,
the effusion disappeared in 29% of Group B cases and 43% of Group C cases (P = 0.03, Group A vs Group C). Furthermore, the 50% survival
period was 1.6 months for Group A, 2.4 months for Group B and 3.5 months for Group C. The 6-month survival rate was 7% for Group A, 6%
for Group B and 34% for Group C, and the 1-year survival rate was 0%, 0% and 17% respectively (P = 0.048, Group A vs Group C by the 
log-rank test). The analysis of the cytokine kinetics revealed a prominent increase in the level of interleukin-6 in the effusion in Group C.
These results suggest that i.c. immunochemotherapy with OK-432 and ACAs may be more beneficial than i.c. chemotherapy alone or
immunotherapy alone.
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reported that effusions from colonic and gastric cancers were
resistant to i.c. chemotherapy and all patients died within 3 months
(Paladine et al, 1976).
Recently, various new agents have been introduced for the treat-
ment of malignant effusion. Among them, i.c. immunotherapy
with streptococcal preparation, OK-432, has been reported to be
very beneficial in controlling malignant effusion (Katano and
Torisu, 1982; Inoue et al, 1993; Torisu et al, 1983; Kawagoe and
Masuda, 1986). OK-432 is a preparation of Streptococcus
pyogenes, type A3, and this agent has been used as an anti-tumour
immunomodulator for gastric, lung and other cancers (Kimura
et al, 1976; Tokai Cooperative Study Group for Adjuvant
Chemoimmunotherapy of Stomach Cancer, 1981; Kim, 1987;
Watanabe and Iwa, 1987; Maehara et al, 1992). The i.c. or
intralesional injection of OK-432 is reported to be effective even
when administered alone (Torisu et al, 1983; Fukuma et al, 1986;
Fujita, 1987); however, intralesional injection of OK-432 also
seems to be beneficial in conjunction with other adjuvant thera-
pies, including radiotherapy (Mukai et al, 1995). This suggests that
the effects of i.c. OK-432 may also be augmented when combined
with other therapies, especially chemotherapy. As far as we know,
there has been only one report on the comparative effects of i.c.
OK-432 and chemotherapy, and it is also reported that i.c. OK-432
for malignant effusion caused by lung cancer achieved a higher
complete response rate (73%) than i.c. mitomycin C (MMC)
(41%); however, there was no significant difference in the median
survival of patients (Luh et al, 1992). There have been no reports
comparing i.c. OK-432 alone and combination therapies with
OK-432 and chemotherapy.
The present study was designed to compare the effects of
OK-432 alone versus chemotherapy alone versus immuno-
chemotherapy with OK-432 and ACAs.
MATERIALS AND METHODS
Registration and randomization of the patients
This clinical study was carried out by the Shimane–Kyoto
Research Group for Cancer Immunochemotherapy, and was open
to patients from August 1992.
Survival was the true end point. We planned for 15 eligible
patients per group to ensure that the trial would have a power (1-b)
of 0.80 to detect a ratio (2.5) of the median survival for Group C to
the median survival for Group A or B based on a clinical report
(Torisu et al, 1983) with a significance level (a) of 0.05 (George
and Desu, 1974; Gehan, 1975).
Several basic criteria had to be met before patients were
included in the study: (1) cytological proof of malignant effusion;
(2) digestive organ cancer or lung cancer as the primary disease;
(3) performance status < 3 (ECOG scale); (4) progressive malig-
nant effusion, which was measurable by physical examination
(abdominal size) or by X-ray, echography, or computerized
tomography (CT).
Contraindications to patient selection included: (1) total
disability (PS = 4, ECOG score); (2) prior chemotherapy, radio-
therapy or immunotherapy within 4 weeks; (3) an active infectious
disease; (4) severe anaemia (haemoglobin < 9.0 g dl–1), leucopenia
(< 3000 mm–3), thrombocytopenia (< 70 000 mm–3), azotemia
(creatinine > 2.0 mg dl–1), or liver dysfunction (GOT, GPT, alka-
line phosphatase levels > four-fold normal limits); (5) an allergy to
penicillin (OK-432 contains penicillin); (6) severe heart disease or
a concomitant malignant disease; and (7) pregnancy. All patients
and their families were fully informed with regard to the experi-
mental nature of the treatment programme, and informed consent
was obtained.
After registration, the patients were randomly assigned to
three groups: Group A – chemotherapy alone, Group B –
immunotherapy alone and Group C – immunochemotherapy,
according to a random number table communicated using a tele-
phone- or fax-based centre-call method. The registration centre
was located at the First Department of Surgery, Shimane Medical
University. The study was supervised by Dr Manabu Fukumoto,
(Associate Professor, First Department of Pathology, Kyoto
University) and the protocol was reviewed by the Ethics
Committee consisting of Dr Norimichi Kan (Rakuyo Hospital,
Kyoto), Dr Kazuhisa Ohgaki (Kyoto Police Hospital, Kyoto) and
Dr Hiroshi Kodama (Kodama Breast Clinic, Kyoto).
Treatment protocol
Under the universal coverage of the Japanese health insurance
system, which was instituted in 1961, ACAs available for clinical
use are specified strictly according to their indications by the
Japanese Ministry of Health and Welfare. We have therefore clas-
sified the ACAs and the primary tumours causing the pleural effu-
sion and ascites in this study according to their indications, when
creating the protocol. The treatment protocol is summarized in
Table 1. Group A patients were treated with i.c. chemotherapy
alone with weekly injections of ACAs; ACAs included cisplatin
(CDDP; Briplatin, Bristol Myers Japan, Tokyo, Japan; or Randa,
Nippon Kayaku, Tokyo, Japan), carboplatin (CBDCA; Bristol
Myers Japan), mitomycin-C (MMC; Kyowa-Hakko Co. Ltd,
Tokyo, Japan), adriamycin (ADR; Kyowa-Hakko), and farmo-
rubicin (EPIR; Kyowa-Hakko). Group B patients received i.c.
immunotherapy alone with weekly injection of streptococcal
preparation, OK-432. Group C patients were treated with i.c.
immunochemotherapy with ACAs and OK-432. The dosage of the
administered agents are summarized in Table 1. ACAs were
diluted in 20–50 ml of distilled water or physiological saline, and
administered directly into the peritoneal or pleural cavity usually
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Table 1 Therapy protocol
Group A (ACA group)
The following ACAs were injected weekly into the peritoneal or pleural cavity,
singly or in combination:
CDDP at 30 mg m–2 (or CBDCA at 300 mg m–2)
MMC at 6 mg m–2
ADR at 30 mg m–2 (or EPIR at 30 mg m–2)
Group B (OK-432 group)
OK-432 at 1~10 KE was injected weekly into the peritoneal or pleural cavity
Group C (ACA and OK-432 group)
One cycle of the regimen included intraperitoneal or intrapleural injections of
ACA on day 1 and OK-432 on day 4; the injections were repeated weekly
The regimens were continued as long as possible. If intracavital injection
became impossible due to the disappearance or decrease of effusion, the
patients received systemic (intravenous or intramuscular) administration of
the agents. ACA, anticancer agent; CDDP, cisplatin; CBDCA, carboplatin;
MMC, mitomycin-C; ADR, adriamycin; EPIR, 4¢-epirubicin; KE, Klinische
Einheit (one KE is equivalent to 0.1 mg of dried cocci).through a silicon catheter, which was inserted into the peritoneal or
pleural cavity under guidance with an echogram. OK-432 is a
penicillin-treated, lyophilized preparation of Streptococcus
pyogenes, group A type 3 (Picibanil, Chugai Pharmaceutical Co.
Ltd, Tokyo, Japan). The Klinische Einheit (KE) is used to express
the dosage of the preparation; 1 KE of OK-432 contains 0.1 mg of
the dried cocci (Sakurai et al, 1972). OK-432 was also adminis-
tered alone or in conjunction with ACAs via a silicon catheter
directly into the peritoneal or pleural cavity. Intracavital injections
of OK-432 were started at a dose of 1–5 KE weekly, and the dose
was gradually increased to 5–10 KE as a maintenance dose
according to the patient’s condition. For patients with a good
performance status, drainage was not performed to avoid hypo-
proteinaemia or dehydration as well as to induce tumour cells and
effusion-associated lymphocytes to react with ACAs and/or
OK-432. If the patients complained of dyspnoea or other serious
effusion-derived symptoms, the effusion was drained until the
symptoms disappeared. According to the advice of the Ethics
Committee, if the malignant effusion disappeared and the agents
could not be injected into the cavity, the ACAs were administered
intravenously (i.v.), or 5-fluorouracil (5-Fu) or its derivatives
(UFT or 5¢-deoxy-fluorouridine) were given orally (p.o.) as a
maintenance chemotherapy for patients in Group A and Group C,
and OK-432 was injected subcutaneously (s.c.) or intramuscularly
(i.m.) at 1–5 KE weekly for patients in Group B and Group C. The
duration of treatment with s.c. or i.m. administration of OK-432
was decided by the doctors with informed consent obtained if
treatment was discontinued.
The examinations of haematology, serum biochemistry, serum
tumour markers and evaluation of symptomatic and performance
status were routinely performed at weekly intervals, sometimes
more frequently. The results of the therapy were assessed every 4
weeks by measurement of abdominal size, X-ray, echogram, CT,
etc. If the disease appeared to progress, the patients were either
managed symptomatically and supportively or offered alternative
experimental regimens if their general condition seemed to be
appropriate.
Evaluation of the response of the effusion to the
therapies
The objective response of the malignant effusion was assessed
using chest X-ray, CT, or echography with the following criteria:
(1) a complete response (CR) indicated a total disappearance of
effusion for at least 4 weeks; (2) a partial response (PR) was
defined as 50% or greater reduction in effusion compared to the
original effusion volume for at least 4 weeks; (3) no change (NC)
indicated less than a 50% reduction in effusion and/or not greater
than a 25% increase in effusion compared to the original volume;
and (4) progressive disease (PD) was defined as greater than a
25% increase of the original effusion volume. The response was
initially evaluated by the investigator at the participating institu-
tion, and then re-evaluated by the supervisor. The duration of
response was measured from the first day of injection of the agents
to the day of increase in the effusion.
Evaluation of the kinetics of cytokines in the effusion
before and after therapy
The kinetics of cytokines in the malignant effusion were assessed.
The cytokines, including tumour necrosis factor alpha (TNF-a),
interleukin-2 (IL-2), interferon gamma (IFN-g) and interleukin-6
(IL-6), were measured at Otsuka Tokyo Assay Laboratories Co.
Ltd, Tokyo, Japan.
Evaluation of side-effects
WHO standard criteria for toxicity (Miller et al, 1981) were used.
The ileus is a well-known side-effect of OK-432 when it is admin-
istered into the peritoneal cavity. This OK-432-associated ileus is
caused by adhesion and is different from paralytic ileus, which is
usually caused by other ACAs. The OK-432-associated ileus
cannot be classified according to the WHO standard criteria, and
the grade of ileus caused by OK-432 was classified according to
our original criteria for bowel obstruction: grade 0, no symptoms;
grade 1, nausea but no vomiting; grade 2, intermittent obstruction
but no intervention and no parenteral nutrition; grade 3, inter-
mittent obstruction, no intervention, but requires parenteral
nutrition; grade 4, complete obstruction, requires intervention
and parenteral nutrition.
Patient follow-up
All the patients were followed up by physical examination, general
X-ray examination, ultrasonography (US), CT, routine haema-
tologic and biochemical examinations, and serum tumour marker
assays.
Statistical evaluation
The effects of the therapies were evaluated with respect to the
response rate of the malignant effusion and the survival rate after
therapy. Chi-square and Mann–Whitney U-tests were used to
compare the backgrounds of patients in the three groups. The
overall survival was calculated by the Kaplan–Meier method
(Kaplan and Meier, 1958). A statistical comparison of the survival
rates among the three groups was made by the generalized
Wilcoxon test (Gehan, 1965) and the log-rank test (Peto et al,
1977). A P-value of less than 0.05 was considered to be signifi-
cant. The statistical analyses were carried out using SAS computer
software.
RESULTS
Patient entry and exclusion for evaluation
Patient entry was stopped in July 1995 because differences in the
survival rates of Group A and Group C were significant. Between
1992 and 1995, a total of 42 patients with malignant effusion were
registered: 41 patients (97.6%) were eligible for statistical
analysis, and one patient of Group B was excluded due to misreg-
istration (the patient was treated with a different immunomodu-
lator). The primary diseases of the eligible patients included 27
gastric, four colorectal, four pancreatic, three lung, two liver and
one oesophageal cancers. Group A included 13 patients, Group B
included 14 patients and Group C included 14 patients. The back-
ground factors of the eligible patients are summarized in Table 2
and there were no differences in the patients’ backgrounds.
Drug administration and toxicity
The administered agents and the doses are summarized in Table 3.
Three kinds of ACAs were administered in Group A: CDDP in
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The mean dose of OK-432 in Group B was 23.9 ± 5.3 KE. Five
kinds of ACAs were administered in Group C patients: CDDP in
ten patients, MMC in three patients, EPIR in two patients,
CBDCA in one patient and 5-FU in one patient. The patients were
administered i.v. or p.o. ACAs and/or i.m. or s.c. OK-432 after a
decrease or disappearance of the malignant effusion. The profiles
of the systemic therapies are summarized in Table 3.
The toxicities and side effects of the regimens are summarized
in Table 4. Toxicity was seen in 46% (6/13) of Group A patients,
and side-effects included the leucopenia, thrombocytopenia, fever,
pain and anorexia. However, none of these toxicities was serious.
In Group B, toxicity of i.c. OK-432 was seen in 29% (4/14) of the
patients, and side-effects included fever, anaemia, leucopenia,
leucocytosis and anorexia. The incidence of side-effects was
highest (57%, 8/14) in Group C, and the toxicities included
anaemia, fever, leucopenia and pain. However, in addition to these
side-effects, OK-432 injection into the peritoneal cavity resulted in
a special problem: two patients suffered from adhesion ileus after
the complete disappearance of ascites. They both needed total
parenteral nutrition even after the disappearance of ascites until
their death due to the recurrence of malignant ascites. However, it
is very difficult to differentiate this kind of ileus from that due to
progression of carcinomatosis.
Responses of malignant effusion
Cytologic examination revealed that tumour cells disappeared in
23% (3/13) of patients in Group A, 36% (5/14) of patients in
Group B and 36% (5/14) of patients in Group C; there were no
differences in cytologic effects (Table 5). The malignant effusion
shrunk after treatment in 31% (4/13) of patients in Group A, but
never disappeared. By contrast, the effusion disappeared in 29%
(4/14) of patients in Group B and 43% (6/14) of patients in
Group C (P = 0.03, Group A vs Group C (Table 5).
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Table 2 Background factors
Protocol
A (n = 13) B (n = 14) C (n = 14)
Sex
Male 8 7 10
Female 5 7 4
Age
< 60 5 2 6
³ 60 8 12 8
Primary disease 7 7 4
Recurrent disease 6 7 10
Effusion
Pleural effusion 3 4 1
Ascites 10 10 11
Both 0 0 2
Origin
Oesophageal 0 1 0
Gastric 11 7 9
Colorectal 0 3 1
Pancreatic 1 2 1
Hepatocellular 0 0 2
Lung 1 1 1
Table 3 Dose of the administered agents
Protocol
A (n = 13) B (n = 14) C (n = 14)
Local injection
OK-432 (KE) 23.9 ± 5.3 (n = 14) 19.2 ± 4.2 (n = 14)
CDDP (mg) 94.4 ± 30.8 (n = 8) 138.9 ± 24.0 (n = 9)
MMC (mg) 16.0 ± 3.1 (n = 4) 9.3 ± 5.5 (n = 3)
EPIR (mg) 185.0 ± 65.0 (n = 2)
CBDCA (mg) 300 (n = 1) 450 (n = 1)
5-FU (mg) 1000 (n = 1)
Systemic injection
OK-432 (i.m.) 17.0 ± 14.4 (n = 4) 33.3 ± 12.7 (n = 4)
CDDP 115.0 ± 15.0 (n = 2) 58.3 ± 22.1 (n = 3)
EPIR 53.3 ± 13.3 (n = 3)
5-FU 3687.5 ± 2035 (n = 4) 2750 ± 1750 (n = 2)
ACA, anticancer agent; CDDP, cisplatin; CBDCA, carboplatin; MMC, mitomycin-C; ADR, adriamycin; EPIR, 4¢-epirubicin; KE,
Klinische Einheit (one KE is 0.1 mg of dried cocci); i.m., intramuscularly.Intracavital immunochemotherapy for malignant effusion 779
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Table 4 Side-effectsa
Incidence (number/total)
Protocol A (n = 13) B (n = 14) C (n = 14)
6/13 (46%) 4/14 (36%) 8/14 (57%)
Fever Overall 0 2 (14%) 4 (29%)
Grade 1 1 1 2
20 1 2
3 ~ 4 0 0 0
Pain Overall 1 (8%) 0 1 (7%)
Grade 1 1 0 0
20 0 1
3 ~ 4 0 0 0
Anorexia Overall 1 (8%) 1 (7%) 1 (7%)
Grade 1 1 1 0
20 0 1
3 ~ 4 0 0 0
Leucopenia Overall 2 (15%) 0 (0%) 2 (14%)
Grade 1 2 0 0
20 0 1
30 0 0
40 0 1
Leucocytosis Overall 0 1 (7%) 1 (7%)
Grade 1 0 1 1
2 ~ 4 0 0 0
Thrombocytopenia Overall 2 (15%) 0 (0%) 1 (7%)
Grade 1 1 0 0
2 ~ 3 0 0 0
41 0 1
Anaemia Overall 1 (8%) 2 (14%) 5 (36%)
Grade 1 1 0 0
20 1 4
30 1 1
40 0 0
Bowel obstructionb Overall 1 (8%) 1 (7%) 2 (14%)
Grade 1 ~ 2 0 0 0
31 0 1
40 1 1
Death 1 (8%)c 00
a According to WHO standard criteria for toxicity. bClassified as described in Materials and Methods. cDue
to acute renal failure caused by CDDP administration.
Table 5 Comparison of therapeutic effects
Protocol
A (n = 13) B (n = 14) C (n = 14)
Response of effusion
a. Objective responsea
CR 0 4 (29%) 6 (43%)
PR 4 (31%) 1 (7%) 3 (21%)
NC 3 4 3
PD 3 0 0
Unevaluableb 35 2
b. Cytologic response
Disappearance 3 (23%) 5 (36%) 5 (36%)
No change 5 2 3
Unevaluableb 57 6
Survival
Median survival days 74 51 115
a P = 0.039 by c2 test. bDue to the patients’ death within 4 weeks after initiation of the therapy. CR,
complete response; PR, partial response; NC, no change; PD, progressive disease.Survival
The 50% survival period was 1.6 months for Group A, 2.4 months
for Group B and 3.5 months for Group C. The 6-month survival
rate was 7% for Group A, 6% for Group B and 34% for Group C,
and the 1-year survival rate was 0%, 0% and 17% respectively
(P = 0.048, Group A vs Group C by log-rank test) (Figure 1).
In the present study, two patients survived for more than 1 year
after initiation of the therapy, and both patients belonged to Group
C. Their clinical courses are summarized in Figures 2 and 3. One
patient (45-year-old male) had massive pleural effusion and
ascites, which were caused by recurrent hepatocellular carcinoma.
He was assigned to Group C and treated with weekly i.p. and i.pl.
injections of EPIR (30 mg m–2) and OK-432 (1 KE per body). The
effusion completely disappeared 6 months later (CR); 3 years have
passed and he is still free from effusion, although the recurrent
tumour still exists but is in remission (Figure 2A–C). Another
patient (85-years-old male) had malignant pleural effusion due to
lung cancer (adenocarcinoma) (Figure 3A). He was also assigned
to Group C, and was treated with a weekly i.pl. injection of EPIR
(10 mg m–2) and OK-432 (1 KE per body). He received injections
a total of 20 times, and the effusion shrunk (MR), but never dis-
appeared. Fortunately, he lived with a good quality of life for more
than 1 year (survival period, 16 months) (Figure 3A–C).
Cytokines in the effusion
The cytokines in the effusion are summarized in Figure 4. In
several patients it was difficult to draw effusion before and after
therapy, due to the death of the patient or the disappearance of
effusion. Accordingly, the kinetics of cytokines were evaluated in
four patients of Group A, three patients of Group B and eight
patients of Group C, both before and after therapy. IL-1a and
IL-1b were not detected in any of the three groups. The level of
IFN-g did not change in Group A; however, it increased threefold
in one patient of Group B and 2.3-fold and 3.3-fold in two patients
of Group C, whose effusion disappeared. The level of TNF-a
increased in one patient of Group A, did not change in any patient
of Group B, and increased in two patients and decreased in two
patients of Group C. The level of IL-6 increased in three patients
of Group A, one patient of Group B and all patients of Group C.
DISCUSSION
The present study demonstrated that i.c. OK-432 alone was more
effective in controlling the malignant effusion than i.c.
chemotherapy alone. Intracavital OK-432 resulted in the disap-
pearance of effusion in 29% of patients; however, i.c.
chemotherapy did not completely eliminate the effusion in any of
the patients. There were no differences in life-prolonging effects
between i.c. chemotherapy and i.c. OK-432, and these therapies
produced no 1-year survivors. There is a report on the comparative
effects of i.c. OK-432 and chemotherapy which reported that
pleurodesis with OK-432 for malignant effusion caused by lung
cancer achieved a higher complete response rate (73%) than did
pleurodesis with MMC (41%); however, there was no significant
difference in the median survival of patients who received the two
treatments (5.8 months for OK-432 and 5.1 months for MMC).
These results are compatible with the present results.
Intracavital OK-432 is a standard regimen for malignant
effusion in Japan. Torisu et al (1983) first reported that i.c. OK-432
was very beneficial in the management of malignant ascites.
Intraperitoneal OK-432 resulted in a mean survival time of 10.2
months and a 50% survival time of 9.0 months compared to 3.1
months and 2.6 months for palliative therapy respectively (Torisu et
al, 1983). They also reported that neutrophil-mediated tumour cell
destruction is one of the mechanisms responsible for the anti-tumour
effects of OK-432 (Katano and Torisu, 1982). Uchida and Micksche
(1983) reported that the cytotoxicity of effusion-associated lympho-
cytes (EAL) was activated against allogeneic and autologous
tumour cells after the i.pl. administration of OK-432 in humans.
Saito et al reported that i.c. OK-432 augmented the LAK activity of
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Figure 1 Survival curves of the three groups. Group A vs Group B: log-rank test; c2 = 0.2106, P = 0.6463. Generalized Wilcoxon test; c2 = 0.3937,
P = 0.5304. Risk ratio (95% CI) = 1.472 (0.606–3.575). Group A vs Group C: log-rank test; c2 = 3.8995, P = 0.0483. Generalized Wilcoxon test; c2 = 3.0496,
P = 0.0808. Risk ratio (95% CI) = 0.652 (0.419–1.014)EAL in mice (Saito et al, 1986). These reports have concentrated on
the immunomodulating effects of OK-432; however, it has also been
reported that OK-432 showed direct cytotoxic and cytostatic effects
on tumour cells (Sakurai et al, 1972; Ono et al, 1973; Nio et al,
1989b). In addition, OK-432 modulates the surface molecules on
tumour cells. It is reported that i.c. administration of OK-432 to
patients with malignant ascites resulted in the enhancement of intra-
cellular adhesion molecule (ICAM)-I expression on tumour cells
(Kitsuki et al, 1994), and that in vitro treatment of tumour cells with
OK-432 resulted in enhanced susceptibility to cytotoxic effector
cells (NK cells and LAK cells) (Nio et al, 1990; Mizutani et al,
1992a). These results suggest that OK-432 may augment the direct
cytotoxicity of EAL against tumour cells as well as the binding of
EAL to tumour cells in malignant effusion.
Although the present study had an important problem in that we
could not use the same ACAs for all protocols due to restrictions
Intracavital immunochemotherapy for malignant effusion 781
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Figure 2 A 45-year-old male patient with malignant pleural effusion and ascites, which were caused by recurrent hepatoma. The patient had been disease-
free for 3 years after right hepatectomy for hepatoma. However, he suddenly suffered from dyspnoea in 1993, and came to our outpatient section. A chest X-ray
examination showed massive pleural effusion (A), and dyspnoea was relieved after removing about 1000 ml of pleural effusion. Cytological examination
revealed malignant cells (hepatoma cells), and an abdominal CT also demonstrated the recurrent hepatomas. He was told that he had malignant effusion in
both the pleural and peritoneal cavities, which was caused by the recurrent hepatoma. He then agreed to the treatment according to the protocol. He was
registered and assigned to Group C and treated with weekly intraperitoneal and intrapleural injections of EPIR (30 mg m–2) and OK-432 (1 KE per body).
At first the effusions seemed to be resistant to the regimen; however, the consistent treatment resulted in the disappearance of effusion after 6 months (CR) (B).
According to his preference, he was treated three times with an intra-arterial injection of lipiodol (2 ml) and EPIR (20 mg) into the hepatic artery.
Three years have passed and he is still free from effusion, although the recurrent tumour still exists (C)imposed by the Japanese national health insurance system, we did
find that i.c. immunochemotherapy with OK-432 and ACAs in
combination was significantly more beneficial than i.c. chemo-
therapy alone or immunotherapy alone. The inhomogeneity of
chemotherapeutic agent selection for the treatment regimens in
Group A and Group C is a major problem in the present study.
This problem might induce the results that the lower response rate
of objective and cytologic responses in Group A. Furthermore, the
possibility that the decrease in Group A’s survival rate might be
due to higher cytotoxicity of ACAs cannot be excluded. However,
this cannot explain the lower rate of objective and cytologic
response, and the doses of the agents administered were not so
different between the Group A and Group C (Table 3).
Accordingly, it seems that the combination of ACAs and OK-432
resulted in the higher rates of objective and cytologic response and
better survival. In the present study, the combination of OK-432
and ACAs achieved complete disappearance of the effusion in
43% of patients, and a 17% 1-year survival rate. This combination
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Figure 3 An 87-year-old male patient with malignant pleural effusion caused by lung cancer. The patient came to our department complaining of dyspnoea,
and chest X-ray and CT examinations revealed massive pleural effusion and lung tumour (A). Cytologic examination also revealed the malignant cells
(adenocarcinoma). He was assigned to Group C. He wanted an ambulatory treatment, and was treated with a weekly puncture of the effusion and an
intrapleural injection of EPIR (10 mg m–2) and OK-432 (1 KE per body), simultaneously. He received injections a total of 20 times, and the effusion shrunk (MR),
but never disappeared (B,C). Fortunately, he did not suffer from dyspnoea, and lived with a good quality of life for more than 1 year. Finally, he died of disease
progression (survival period, 16 months)regimen with ACA and OK-432 achieved a higher response rate
and survival rate than did ACA or OK-432 alone. Several investi-
gators reported the beneficial effects of combinations of OK-432
and ACAs: the survival rate of patients with lung cancer was
higher after treatment with chemotherapy and OK-432 than after
treatment without OK-432 (Kimura et al, 1976). The survival
of patients receiving immunochemotherapy with intradermal
OK-432 and ACAs was significantly better than that of matched
control patients given chemotherapy alone (Uchida and Hoshino,
1980). The survival of patients with gastric cancer, who were
administered intramuscular OK-432 in addition to the adjuvant
chemotherapy after gastrectomy, was significantly better than that
of patients who received adjuvant chemotherapy alone (Kim,
1987); a statistically significant improvement of the survival rate
after lung cancer surgery was seen in patients treated with OK-432
alone or OK-432 and chemotherapy in comparison with the
patients who were treated with chemotherapy alone (Watanabe and
Iwa, 1987); and, a post-surgical adjuvant immunochemotherapy
with oral OK-432 and MMC + 5-FU derivatives after curative
resection of the gastric cancer resulted in a significantly better
survival in comparison with chemotherapy alone (Kyoto Research
Group for Digestive Organ Surgery, 1992). The mechanisms
responsible for the benefits of the combination of OK-432 and
chemotherapy are unclear. There are several possibilities: (1)
OK-432 augments the anti-tumour effect of ACAs, because
OK-432 itself has a direct cytotoxic and cytostatic activity against
tumour cells and inhibits DNA and RNA syntheses in tumour cells
(Ono et al, 1973; Nio et al, 1990); (2) chemotherapy increases the
susceptibility of tumour cells to cytotoxic effecter cells including
lymphocytes, macrophages and neutrophils activated by OK-432
through direct damage or modulation of surface antigens by
chemotherapy (Ujiie, 1989; Mizutani et al, 1992b); (3) ACAs,
including ADR and CDDP, directly augment the cytotoxic activity
of the effecter cells under certain conditions (Kleinerman et al,
1980; Ehrke et al, 1984), although ACAs usually inhibit the gener-
ation of cytotoxic effecter cells (Mantovani et al, 1978; Allavena et
al, 1990); and (4) ACAs eliminate the suppressor cells or
suppressor factor in the blood or effusion (Heppner and Calabresi,
1972; Goto et al, 1981), resulting in augmented anti-tumour
activity of OK-432-activated immunopotentiating cells, especially
T-cells (Nio et al, 1989a; Bier, 1987; Bier and Bier, 1987). The
present immunological study demonstrated that the combination
of ACA and OK-432 in Group C resulted in a prominent increase
in the level of IL-6 in the effusion. These changes in cytokine
levels suggest that immunological responses were caused by the
agents. The increase in the level of IL-6 may induce the differenti-
ation and proliferation of various lymphoid cells, especially B-
cells, which was seen in all three groups. However, the increase in
the level of IL-6 was more prominent in Group C. The increase in
the level of IL-6 may be a non-specific inflammatory reaction
caused by ACAs and/or OK-432. These results suggest that the
immunological reaction might be caused more strongly by the
combination of ACAs and OK-432. Accordingly, all of the above
mechanisms may be responsible for the combination effects of
OK-432 and ACAs.
OK-432 is known to induce a serious adhesion or sclerosis of
the peritoneum and pleura when administered into the peritoneal
or pleural cavity. Accordingly, i.c. administration of OK-432 has
been applied to manage refractory spontaneous pneumothorax.
Furthermore, the intracystic injection of OK-432 is reported to be
very beneficial for sclerosing therapy of neck cystic hygroma in
children (Ogita et al, 1987). These sclerosing effects of OK-432 on
the peritoneum and pleura may be derived from the inflammations
caused by OK-432. However, the effects sometimes cause serious
ileus when OK-432 is administered into the peritoneal cavity. In
this study, two patients (one patient in Group B and one patient in
Group C) suffered from serious ileus and received total parenteral
nutrition although their ascites completely disappeared. The ileus
impairs the quality of life (QOL) of the patient, even if the malig-
nant effusion completely disappears. However, the QOL is depen-
dent on the patients’ background such as age, social status and
previous course of the disease. For example, one of the patients did
not voice strong objections to parenteral nutrition and ileus symp-
toms, since he was pleased to receive relief from effusion and
dyspnoea. Because he had suffered from serious abdominal disten-
sion and dyspnoea, and sometimes needed oxygen therapy, the
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Figure 4 Cytokines in effusion. x - - - - x, Group A (chemotherapy alone); D¾D, Group B (OK-432 alone); O¾O, Group C (chemotherapy + OK-432)effusion and dyspnoea had also impaired his QOL seriously.
However, the other patient suffered from serious vomiting and was
continuously drained of gastric and bowel juices. Group C patients
enjoyed a survival benefit and a high rate of complete disappear-
ance of effusion. The Group B protocol showed the latter
advantage, but no survival benefit, compared with Group A.
Balancing the advantages and disadvantages (potential for ileus),
the protocol of Group B cannot be justified compared with that
of Group A. Accordingly, OK-432 should be administered in
combination with ACAs for malignant effusion, and the
duration and frequency of i.c. OK-432 administration are key
factors for the successful treatment of malignant ascites without
adhesion ileus.
In conclusion, the peritoneal or pleural cavity is a restricted
space and agents injected i.c. may accumulate in the cavity more
easily and efficiently than those injected systemically.
Accordingly, immunologic or cytological reactions may be more
pronounced after i.c. injection of OK-432 and ACAs than after
systemic administration.
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